WithdrawnPhase 3

Tranexamic Acid (TXA) in Hip Arthroscopy

Stopped: Study was never started. Did not receive funding.

United States0Started 2023-12

Plain-language summary

The primary goal of this study will be to determine if perioperative IV Tranexamic Acid (TXA) administration will reduce intra-operative bleeding and subsequently improve visual clarity during surgery and reduce operative traction time in patients undergoing hip arthroscopy. Additionally, this study aims to determine whether IV TXA injections will reduce post-operative pain and affect hip-specific patient-reported outcomes in patients undergoing hip arthroscopy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older * Scheduled to undergo primary hip arthroscopy for any intra-articular procedure * Able to complete and understand study materials in English Exclusion Criteria: * Age under 18 years * Cannot complete and understand study materials in English * Patients undergoing revision surgery * Patients who have had previous surgery to the study joint * Patients on drugs that interfere with coagulation or TXA clearance * Patients with a known allergy to TXA * Patients with any of the following comorbidities * Bleeding and/or coagulative disorders * Renal impairment * Sickle cell disease * Thrombotic diseases * Comorbidities preventing surgery (including pregnancy)

What they're measuring

Visual clarity grade

Timeframe: Throughout surgical procedure

Trial details

NCT IDNCT05710146

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03

View on ClinicalTrials.gov More Hip Pain Chronic trials